Latest Pharma Insights
Tariffs Drag Down Profits For Cardinal’s Medical Products Division, Even As Overall Revenues Up 11%
Cardinal Health presented a mixed financial picture during its April 30 earnings call. A lower valuation for Cardinal’s Navista & ION business dropped earnings, even as strong sales across pharmaceuticals, home care and nuclear medicine softened the blow. Overall revenues were up 11% year-over-year.
Medtech Insight - May 2, 2026
Cardinal Health presented a mixed financial picture during its April 30 earnings call. A lower valuation for Cardinal’s Navista & ION business dropped earnings, even as strong sales across pharmaceuticals, home care and nuclear medicine softened the blow. Overall revenues were up 11% year-over-year.
Medtech Insight - May 2, 2026
Auvelity Will Take On Rexulti After FDA Nod For Alzheimer’s-Related Agitation
Analysts predict the supplemental indication could add more than $1bn in sales for the major depressive disorder drug. Axsome projects a launch in June.
Scrip - May 1, 2026
Analysts predict the supplemental indication could add more than $1bn in sales for the major depressive disorder drug. Axsome projects a launch in June.
Scrip - May 1, 2026
Finance Watch: Avalyn, Hemab And Seaport Launch $856m Worth Of IPOs
Public Company Edition: Avalyn, Hemab and Seaport grossed $300m, $301.5m and $254.9m, respectively, bringing this year’s biopharma US IPO total to 10. Also, Oruka garnered $700m, Veradermics brought in $384.4m and Intellia raised $180m in post-data follow-on offerings.
Scrip - May 1, 2026
Public Company Edition: Avalyn, Hemab and Seaport grossed $300m, $301.5m and $254.9m, respectively, bringing this year’s biopharma US IPO total to 10. Also, Oruka garnered $700m, Veradermics brought in $384.4m and Intellia raised $180m in post-data follow-on offerings.
Scrip - May 1, 2026
J&J Drops Two Lymphoma CAR-Ts, Citing Portfolio Priorities, Treatment Landscape
The company said it would discontinue development of prizlo-cel and JNJ-9530, which it licensed in 2023, even though prizlo-cel has demonstrated strong efficacy in LBCL.
Scrip - May 1, 2026
The company said it would discontinue development of prizlo-cel and JNJ-9530, which it licensed in 2023, even though prizlo-cel has demonstrated strong efficacy in LBCL.
Scrip - May 1, 2026
Summit’s Bet On Early Success For Ivonescimab Falls Flat
A bid to fast track the PD-1xVEGF candidate in non-small cell lung cancer has failed – and raises the stakes for partner Akeso’s upcoming ASCO presentation.
Scrip - May 1, 2026
A bid to fast track the PD-1xVEGF candidate in non-small cell lung cancer has failed – and raises the stakes for partner Akeso’s upcoming ASCO presentation.
Scrip - May 1, 2026
UniQure Targets UK Okay For Huntington’s Gene Therapy After FDA Clashes
The firm is looking to file AMT-130 with the MHRA with the same data package that has been rejected by the US regulator.
Scrip - May 1, 2026
The firm is looking to file AMT-130 with the MHRA with the same data package that has been rejected by the US regulator.
Scrip - May 1, 2026
Scrip M&A Podcast: What Can We Infer From The First Quarter’s Late Deal Flurry
With Cooley LLP partners Kevin Cooper and Bill Roegge, Scrip’s Joseph Haas discussed the current state of biopharma M&A, how smaller companies can negotiate a solid buyout and whether competitive bids may become more common.
Scrip - May 1, 2026
With Cooley LLP partners Kevin Cooper and Bill Roegge, Scrip’s Joseph Haas discussed the current state of biopharma M&A, how smaller companies can negotiate a solid buyout and whether competitive bids may become more common.
Scrip - May 1, 2026
Chugai Focuses On Innovation Capabilities As Its Logs Solid Q1
After a quarter which saw good growth at home and abroad, Chugai looks to the global progress of orforglipron through Lilly and stresses an investment focus on R&D and late-stage assets.
Scrip - May 1, 2026
After a quarter which saw good growth at home and abroad, Chugai looks to the global progress of orforglipron through Lilly and stresses an investment focus on R&D and late-stage assets.
Scrip - May 1, 2026
Tariffs Drag Down Profits For Cardinal’s Medical Products Division, Even As Overall Revenues Up 11%
Cardinal Health presented a mixed financial picture during its April 30 earnings call. A lower valuation for Cardinal’s Navista & ION business dropped earnings, even as strong sales across pharmaceuticals, home care and nuclear medicine softened the blow. Overall revenues were up 11% year-over-year.
Medtech Insight - May 2, 2026
Cardinal Health presented a mixed financial picture during its April 30 earnings call. A lower valuation for Cardinal’s Navista & ION business dropped earnings, even as strong sales across pharmaceuticals, home care and nuclear medicine softened the blow. Overall revenues were up 11% year-over-year.
Medtech Insight - May 2, 2026
Lauder Expands Restructuring, ‘Right-Sizes’ Department Store Footprint
The Estée Lauder Companies estimates a final net reduction in employee positions of up to 10,000, from an initial target of up to 7,000, under its restructuring program.
HBW Insight - May 1, 2026
The Estée Lauder Companies estimates a final net reduction in employee positions of up to 10,000, from an initial target of up to 7,000, under its restructuring program.
HBW Insight - May 1, 2026
IQVIA Consumer Health: Rx-To-OTC Switch ‘Back On The Agenda’ In Europe
IQVIA Consumer Health argues that mounting pressure on European health systems is driving a new era of Rx-to-OTC switch, and that smarter use of real-world evidence and an expanded pharmacist role could unlock the next wave of reclassifications.
HBW Insight - May 1, 2026
IQVIA Consumer Health argues that mounting pressure on European health systems is driving a new era of Rx-to-OTC switch, and that smarter use of real-world evidence and an expanded pharmacist role could unlock the next wave of reclassifications.
HBW Insight - May 1, 2026
US Consumer Health News Digest: Business, Regulation, Science
HBW Insight notes recent news from across the US consumer health industry and marketplace in our latest weekly digest.
HBW Insight - May 1, 2026
HBW Insight notes recent news from across the US consumer health industry and marketplace in our latest weekly digest.
HBW Insight - May 1, 2026
Indoco Refocuses With ‘Non-Core’ India And Africa Divestment
Indoco Remedies is divesting its ophthalmic division across India and Africa for INR1.1bn, sharpening its focus on core therapies, as Sunways scales its ophthalmology platform through a strategically aligned bolt-on acquisition.
Generics Bulletin - May 1, 2026
Indoco Remedies is divesting its ophthalmic division across India and Africa for INR1.1bn, sharpening its focus on core therapies, as Sunways scales its ophthalmology platform through a strategically aligned bolt-on acquisition.
Generics Bulletin - May 1, 2026
Henlius-Organon Wins EU’s First Perjeta Biosimilar Approval
The approvals of the Poherdy (pertuzumab) biosimilar on two continents cement Henlius and Organon as the team to beat in the pertuzumab biosimilar race – whenever that race officially starts.
Generics Bulletin - May 1, 2026
The approvals of the Poherdy (pertuzumab) biosimilar on two continents cement Henlius and Organon as the team to beat in the pertuzumab biosimilar race – whenever that race officially starts.
Generics Bulletin - May 1, 2026
Teva Meets European Ambition On Olanzapine
Teva is continuing to advance its long-acting olanzapine, with a filing now complete in Europe. The firm’s generics sales slumped in Q1 due to lenalidomide but biosimilars growth and pipeline expansion signal longer-term upside.
Generics Bulletin - May 1, 2026
Teva is continuing to advance its long-acting olanzapine, with a filing now complete in Europe. The firm’s generics sales slumped in Q1 due to lenalidomide but biosimilars growth and pipeline expansion signal longer-term upside.
Generics Bulletin - May 1, 2026
What’s Next? Five Things To Look Out For In May
Generics Bulletin previews the most noteworthy and anticipated events for May 2026.
Generics Bulletin - May 1, 2026
Generics Bulletin previews the most noteworthy and anticipated events for May 2026.
Generics Bulletin - May 1, 2026
Podcast: Carna Health On Closing the Gap in CKD Prevention
Salvatore Viscomi, CEO and co-founder of Carna Health, discussed the company's pivotal work to combat the global crisis of chronic kidney disease (CKD).
In Vivo - May 1, 2026
Salvatore Viscomi, CEO and co-founder of Carna Health, discussed the company's pivotal work to combat the global crisis of chronic kidney disease (CKD).
In Vivo - May 1, 2026